Read the story here. Advertise at Before It's News here.
Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views
Last hour:
Last 24 hours:

MindMed successfully completes pre-IND meeting with FDA on development of LSD-assisted therapy for an anxiety disorder

% of readers think this story is Fact. Add your two cents.

Mind Medicine (MindMed) Inc (NEO:MMED) (OTCQB:MMEDF) (FRA:MMQ) announced Monday the successful completion of a pre-Investigational New Drug pre-IND) meeting with the US Food and Drug Administration (FDA) on the development of LSD-assisted therapy for an anxiety disorder. 

In a statement, the company said the successful engagement with the FDA is an important milestone and provides regulatory clarity and confidence as MindMed advances its lead clinical development program in the US. 

MindMed said it intends to open the IND with the FDA in August 2021 with a Phase 2b clinical trial (called Project Lucy) evaluating experiential doses of LSD in an anxiety disorder. 

READ: MindMed launches digital medicine division Albert to weave together technology and psychedelics

“The FDA is one of the most impactful organizations for regulated drug development globally,” said MindMed Co-Founder & Co-CEO JR Rahn. “We look forward to working through the FDA pathway on psychedelic-assisted therapies in strict compliance with their proven drug development guidelines and commencing our Phase 2b trial for Project Lucy in 2021.”

In other company news, MindMed said preliminary data has been analyzed for its addiction treatment program evaluating the ibogaine derivative 18-MC, which the company has named Project Layla. 

The New York City-based company said preliminary data from the Phase 1 Multiple Ascending Dose and Single Ascending Dose study has shown that the drug is safe and well-tolerated at the doses tested to date, and no Serious Adverse Events reported.

Based on the excellent safety profile observed to date, MindMed said its clinical team and 18-MC’s medical director, Dr Judy Ashworth, have decided to continue dose escalation in the study to gather higher dosing data.

Once that additional data has been reviewed, MindMed said it will directly initiate the Phase 2a proof of concept study. A meeting with the FDA has been confirmed to continue discussions regarding the 18-MC clinical development plan.

The company’s stock recently traded 16% higher to $4.17 a share in New York.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Story by ProactiveInvestors


Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world.

Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.

"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.

Please Help Support BeforeitsNews by trying our Natural Health Products below!

Order by Phone at 888-809-8385 or online at M - F 9am to 5pm EST

Order by Phone at 888-809-8385 or online at M - F 9am to 5pm EST

Humic & Fulvic Trace Minerals Complex - Nature's most important supplement! Vivid Dreams again!

HNEX HydroNano EXtracellular Water - Improve immune system health and reduce inflammation

Ultimate Clinical Potency Curcumin - Natural pain relief, reduce inflammation and so much more.

MitoCopper - Bioavailable Copper destroys pathogens and gives you more energy. (See Blood Video)
Oxy Powder - Natural Colon Cleanser!  Cleans out toxic buildup with oxygen! 
Nascent Iodine - Promotes detoxification, mental focus and thyroid health.
Smart Meter Cover -  Reduces Smart Meter radiation by 96%!  (See Video)

Immusist Beverage Concentrate - Proprietary blend, formulated to reduce inflammation while hydrating and oxygenating the cells.

Report abuse


    Your Comments
    Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

    Load more ...




    Email this story
    Email this story

    If you really want to ban this commenter, please write down the reason:

    If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.